New study aims to help older breast cancer patients cope with treatment side effects
NCT ID NCT07232056
First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times
Summary
This study tests two support programs for women aged 65 and older with hormone-sensitive breast cancer who are taking aromatase inhibitors. The programs include a clinic-level geriatric assessment and support, and a telehealth coping skills training based on cognitive behavioral therapy. The goal is to reduce pain and improve quality of life. The trial plans to enroll 452 participants across multiple sites.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Geriatric oncology assessment and support program (GOAL-AI) and CBT-based coping skills training (CST-AI)
- What this could lead to
- If successful, these programs could provide a practical way to reduce pain and improve daily life for older women on hormone therapy.
- What could go wrong
- This is a behavioral intervention trial, so results depend on participant engagement and may not apply to all patients. The study has not yet started recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 452 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female, age ≥65 years * HR+ non-metastatic breast cancer * Within 12 months of starting AI therapy * English-speaking * Able to provide consent Exclusion Criteria: * Age \<65 years * Metastatic cancer * Cognitive impairment preventing consent * Receiving care at multiple participating sites
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer, hormone receptor positive, aromatase inhibitor-associated arthralgia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.